„Terapia szokowa”, czyli agoniści receptor 5-HT2A w leczeniu depresji i lęku
Streszczenie
The most widespread ailment that affects people nowadays are depressive and anxiety disorder, which
may concern even 20% of the population. Profits of pharmaceutical companies from drug trade on theseailments are among the biggest, which shows a large scale of the problem. The most commonly useddrugs in these cases are SSRIs - selective serotonin reuptake inhibitors, whose antidepressant andanxiolytic effects are mainly based on change in density of some receptors, which translates into areduction intensity of emotions. However, recently researchers have turned to drugs that acts reverse to
SSRIs. These substances are psychedelics, for instance LSD, psilocybin and ayahuasca, which are 5HT2A receptor agonists in the central nervous system. It turns out that substances which almost alcountries of the world are illegal, properly used can have therapeutic properties, and this action is based
not on suppressing emotions and thoughts, but on increasing their intensity. This allows in some wayunderstand and work on the disorder. Following text presents a brief description of depression andanxiety, psychedelics pharmacodynamics and safety of their use. Then we discussed some of thecompounds most commonly used in research and possible scientific explanations why they work
therapeutically. There are presented also SSRIs mechanism of action and their comparison with
psychedelics, both in terms of receptor activity or different molecules in the brain, as well as in
subjective perceptions of the effects.
Kolekcje
- Artykuły / Articles [16165]
Korzystanie z tego materiału jest możliwe zgodnie z właściwymi przepisami o dozwolonym użytku lub o innych wyjątkach przewidzianych w przepisach prawa, a korzystanie w szerszym zakresie wymaga uzyskania zgody uprawnionego.